Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone.
about
Role of exosomes/microvesicles in the nervous system and use in emerging therapiesImmune Evasion Strategies of GlioblastomaPaving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the FateA conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma CareSeverity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomasRegulatory myeloid cells in transplantationA method for identification and analysis of non-overlapping myeloid immunophenotypes in humansCheckpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous SystemImmunotherapy response assessment in neuro-oncology: a report of the RANO working groupInfluence of caloric restriction on constitutive expression of NF-κB in an experimental mouse astrocytomaPattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma.A nested case-control study of 277 prediagnostic serum cytokines and glioma.Strategies for improving the reporting of human immunophenotypes by flow cytometry.Overview of cellular immunotherapy for patients with glioblastoma.Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risksCUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoringSystemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer PatientsGeneration of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival timeVictory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphomaIncreased CTLA-4(+) T cells and an increased ratio of monocytes with loss of class II (CD14(+) HLA-DR(lo/neg)) found in aggressive pediatric sarcoma patientsAssociation of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL).Systemic T Cells Immunosuppression of Glioma Stem Cell-Derived Exosomes Is Mediated by Monocytic Myeloid-Derived Suppressor Cells.Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma modelMyeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancerGlioma stem cells and immunotherapy for the treatment of malignant gliomas.Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cellsInfluence of human immune cells on cancer: studies at the University of Colorado.Immunological monitoring of the tumor immunoenvironment for clinical trials.Clinical trials in cellular immunotherapy for brain/CNS tumors.Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)HLA-DR(lo/neg) Cells): The Gateway to Improved Responses.T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion.The role of regulatory T cells and microglia in glioblastoma-associated immunosuppression.Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis.Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin.Assessment of Brain Tumor Response: RANO and Its Offspring.Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells.Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model.
P2860
Q21129255-9CF1D739-F672-483B-88B3-5CEB2304F6B4Q26765855-48A09D42-5378-41C8-94CE-F58C55C394D3Q26777205-9883A31D-3DC5-44C5-A1F1-1DD8816E9498Q26851160-F6A6350E-C9B7-4E19-8B36-50B686C8656AQ26862551-8785F5D7-4106-4E65-986C-B10D5B111CBCQ26999875-BEBA1612-41A9-40A9-A178-42066E21B1ECQ27310807-6367749A-BE42-47D9-B4EA-FA798520E13EQ28066906-79F800CF-5603-4CC8-A96E-A3E179E963C3Q28083009-A2880F24-DF12-4ACF-BB4B-C1ACA6452263Q28477560-F9A0B0B2-3458-4265-90D1-BCF62BA68CD4Q33759661-2ACAFD81-996B-4039-A8A4-D697989506F0Q33778545-BB3271BF-2D90-4653-9A46-B264D5D1B57BQ33822690-1C20C6B9-C1B2-4E6A-975D-263023263220Q34189694-907CCD76-151D-41D1-8EBB-422A2687B18CQ34316147-611600FC-A2A8-44E2-96C4-FA063C631087Q34437996-ABBFAC28-3C86-46DF-AE20-ED9426CF96BBQ34557531-D62EA687-A9B5-4D8D-93DB-1D3BD3185CC4Q35629271-9567E835-4FD6-4185-8D4C-992EC8C497A2Q35759682-54A2D451-A8F8-42B9-97F2-210787DC24ACQ35772513-05A6227A-638B-445D-8DBE-B1C5C3886D29Q35799695-1D9962FB-A31B-40A7-AE82-547DF11C4D74Q35921894-9B84252A-C7A0-49B1-AFD7-208D7337532EQ35965142-D5D27E64-A1C7-456A-A2BA-46FB3A6F54AAQ36206949-560F3EEA-124B-4FCC-9AE9-BCD4A5808BC6Q36255674-E80F53CD-3228-4AD4-8183-DE5B71EC5D54Q36514324-0BC4548E-417C-4630-B7AC-CB950F66C835Q36896764-E5C65517-DA23-40E0-9C7B-367157458290Q36898699-72D46DED-0F44-4F56-BF49-43F8FAA84567Q37079098-F8F055D0-C7FA-421A-A1F9-E08854CAF125Q37698684-E237E2B1-928D-4E3A-9866-AD4DE4DF697DQ37955680-6B756B5F-F095-45B7-93CE-7A705A2444BDQ38094811-FB4C00AB-373C-41ED-81DC-47E333A11FAFQ38207587-E639DB66-4D4B-47BE-A41E-DB309D8B5B08Q38344066-C2AA1A8E-A202-4CF7-8117-EB25B375230FQ38540262-E351699A-7A7B-46DA-9CA7-7A6C6E89BDE6Q38662119-15779E53-0655-4BEE-A18D-7EB8D82B9168Q38811369-86D9CD8B-83D0-4276-BFF5-D9EB603060D2Q38855020-212AE86A-D9CE-4E7D-B3C0-673669F34FC1Q38895952-12E193A8-CD38-4449-979E-1B2CD3D54925Q38925761-B629A575-3684-45BB-80C4-A7B960ED7C6D
P2860
Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Systemic immune suppression in ...... or factors, and dexamethasone.
@en
type
label
Systemic immune suppression in ...... or factors, and dexamethasone.
@en
prefLabel
Systemic immune suppression in ...... or factors, and dexamethasone.
@en
P2093
P2860
P356
P1433
P1476
Systemic immune suppression in ...... or factors, and dexamethasone.
@en
P2093
Brian Patrick O'Neill
Dennis A Gastineau
Kent C New
Michael P Gustafson
Peggy A Bulur
P2860
P304
P356
10.1093/NEUONC/NOQ001
P577
2010-02-23T00:00:00Z